拮抗剂-话题@MedSci

#拮抗剂#

223篇内容 | 4458人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Nat Med：CXCR4拮抗剂+PD-1抑制剂+化疗三联疗法治疗胰腺癌获突破, objectType=article, longId=194893, objectId=9c8d19489351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c8d19489351, replyNumber=0, likeNumber=88, createdTime=2020-05-29, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c8d19489351, moduleTitle=Nat Med：CXCR4拮抗剂+PD-1抑制剂+化疗三联疗法治疗胰腺癌获突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c8d19489351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511760, encodeId=c9aa1511e606a, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Eur Heart J-Card Img：主动脉瓣钙化与维生素K拮抗剂治疗的关联, objectType=article, longId=193581, objectId=2615193581c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2615193581c1, replyNumber=0, likeNumber=90, createdTime=2020-05-08, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2615193581c1, moduleTitle=Eur Heart J-Card Img：主动脉瓣钙化与维生素K拮抗剂治疗的关联, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2615193581c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511759, encodeId=bcb61511e597c, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Brit J Cancer：质子泵抑制剂和组胺-2受体拮抗剂与胃癌风险, objectType=article, longId=193538, objectId=ec7f19353856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec7f19353856, replyNumber=0, likeNumber=85, createdTime=2020-05-07, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec7f19353856, moduleTitle=Brit J Cancer：质子泵抑制剂和组胺-2受体拮抗剂与胃癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec7f19353856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511758, encodeId=de2c1511e5899, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Brit J Heamatol：静脉血栓栓塞门诊患者维生素K拮抗剂治疗期间大出血的预测, objectType=article, longId=193403, objectId=681819340340, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=681819340340, replyNumber=0, likeNumber=77, createdTime=2020-05-04, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=681819340340, moduleTitle=Brit J Heamatol：静脉血栓栓塞门诊患者维生素K拮抗剂治疗期间大出血的预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=681819340340)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511757, encodeId=b8d71511e577f, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=3期临床研究证实，促性腺激素释放激素（GnRH）受体拮抗剂Relugolix 显着减轻子宫内膜异位症女性的疼痛, objectType=article, longId=192962, objectId=cdb5192962b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdb5192962b6, replyNumber=0, likeNumber=54, createdTime=2020-04-27, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdb5192962b6, moduleTitle=3期临床研究证实，促性腺激素释放激素（GnRH）受体拮抗剂Relugolix 显着减轻子宫内膜异位症女性的疼痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdb5192962b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511756, encodeId=00621511e5676, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Hypertension：IL-1受体拮抗剂可增加肥胖个体Ang（1-7)水平并降低血压, objectType=article, longId=192113, objectId=ac2e192113e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac2e192113e5, replyNumber=0, likeNumber=61, createdTime=2020-04-14, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac2e192113e5, moduleTitle=Hypertension：IL-1受体拮抗剂可增加肥胖个体Ang（1-7)水平并降低血压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac2e192113e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511755, encodeId=1a321511e5575, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Ann Neurol：近期缺血性脑卒中的房颤患者直接口服抗凝剂与维生素K拮抗剂比较, objectType=article, longId=191624, objectId=c5ba19162425, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5ba19162425, replyNumber=0, likeNumber=89, createdTime=2020-04-08, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5ba19162425, moduleTitle=Ann Neurol：近期缺血性脑卒中的房颤患者直接口服抗凝剂与维生素K拮抗剂比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5ba19162425)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511754, encodeId=ade11511e545b, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=IL-5拮抗剂Nucala治疗慢性鼻-鼻窦炎的临床试验：取得阳性结果, objectType=article, longId=191477, objectId=26091914e7bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26091914e7bf, replyNumber=0, likeNumber=83, createdTime=2020-04-06, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26091914e7bf, moduleTitle=IL-5拮抗剂Nucala治疗慢性鼻-鼻窦炎的临床试验：取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26091914e7bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511753, encodeId=a2211511e5391, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, objectType=article, longId=191239, objectId=94ff191239b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94ff191239b4, replyNumber=0, likeNumber=83, createdTime=2020-04-03, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94ff191239b4, moduleTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94ff191239b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511752, encodeId=07bb1511e52f9, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Minerva Medica: ACEI与钙拮抗剂复方降压更优！意大利学者质疑欧洲指南：ARB和钙拮抗剂无证据, objectType=article, longId=189005, objectId=a07f18900552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a07f18900552, replyNumber=0, likeNumber=76, createdTime=2020-03-01, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a07f18900552, moduleTitle=Minerva Medica: ACEI与钙拮抗剂复方降压更优！意大利学者质疑欧洲指南：ARB和钙拮抗剂无证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a07f18900552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511751, encodeId=54a61511e51c3, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Clin Gastroenterology H：肿瘤坏死因子拮抗剂治疗难治性溃疡性直肠炎的疗效, objectType=article, longId=188661, objectId=f1ee18866149, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1ee18866149, replyNumber=0, likeNumber=62, createdTime=2020-02-25, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1ee18866149, moduleTitle=Clin Gastroenterology H：肿瘤坏死因子拮抗剂治疗难治性溃疡性直肠炎的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1ee18866149)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511750, encodeId=e97a1511e50a5, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=强生的雄激素受体拮抗剂Erleada，获得欧洲药品管理局批准治疗去势敏感型前列腺癌, objectType=article, longId=187284, objectId=4eb418e284e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eb418e284e5, replyNumber=0, likeNumber=78, createdTime=2020-02-04, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eb418e284e5, moduleTitle=强生的雄激素受体拮抗剂Erleada，获得欧洲药品管理局批准治疗去势敏感型前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eb418e284e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511749, encodeId=f7c51511e497b, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Blood：MYC驱动的淋巴瘤进展需MYC拮抗剂MNT抑制MYC诱导的细胞凋亡, objectType=article, longId=187108, objectId=431a18e108fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431a18e108fe, replyNumber=0, likeNumber=96, createdTime=2020-02-03, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431a18e108fe, moduleTitle=Blood：MYC驱动的淋巴瘤进展需MYC拮抗剂MNT抑制MYC诱导的细胞凋亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=431a18e108fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511748, encodeId=d9a31511e4833, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=FDA授予β3-肾上腺素能受体拮抗剂APD418用于代偿性心力衰竭治疗的快速通道指定, objectType=article, longId=186459, objectId=09c218645948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09c218645948, replyNumber=0, likeNumber=72, createdTime=2020-01-19, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09c218645948, moduleTitle=FDA授予β3-肾上腺素能受体拮抗剂APD418用于代偿性心力衰竭治疗的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09c218645948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511747, encodeId=9b151511e474d, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=BMJ：质子泵抑制剂和组胺受体拮抗剂对胃肠道出血的预防效果, objectType=article, longId=185883, objectId=3d1e18588369, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d1e18588369, replyNumber=0, likeNumber=68, createdTime=2020-01-09, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d1e18588369, moduleTitle=BMJ：质子泵抑制剂和组胺受体拮抗剂对胃肠道出血的预防效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d1e18588369)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511746, encodeId=4fbb1511e4610, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Oncogene：拮抗剂贝沙罗汀靶向TR4核受体能够增加前列腺癌对多烯紫杉醇的敏感性, objectType=article, longId=184301, objectId=1ec6184301de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ec6184301de, replyNumber=0, likeNumber=62, createdTime=2019-12-06, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ec6184301de, moduleTitle=Oncogene：拮抗剂贝沙罗汀靶向TR4核受体能够增加前列腺癌对多烯紫杉醇的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ec6184301de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511745, encodeId=c9a01511e45c1, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Myovant口服促性腺激素释放激素拮抗剂relugolix的前列腺癌III期试验成功, objectType=article, longId=183428, objectId=910418342888, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=910418342888, replyNumber=0, likeNumber=84, createdTime=2019-11-24, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=910418342888, moduleTitle=Myovant口服促性腺激素释放激素拮抗剂relugolix的前列腺癌III期试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=910418342888)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511744, encodeId=18441511e4426, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=阿斯利康的P2Y12受体拮抗剂Brilinta单一疗法可降低急性冠状动脉综合症患者的出血风险, objectType=article, longId=183283, objectId=416a18328369, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=416a18328369, replyNumber=0, likeNumber=85, createdTime=2019-11-21, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=416a18328369, moduleTitle=阿斯利康的P2Y12受体拮抗剂Brilinta单一疗法可降低急性冠状动脉综合症患者的出血风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=416a18328369)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511743, encodeId=71051511e43d3, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=Science：谷氨酰胺拮抗剂——“代谢检查点”广谱抗癌药曙光初现, objectType=article, longId=182889, objectId=966b182889aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=966b182889aa, replyNumber=0, likeNumber=71, createdTime=2019-11-14, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=966b182889aa, moduleTitle=Science：谷氨酰胺拮抗剂——“代谢检查点”广谱抗癌药曙光初现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=966b182889aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1511742, encodeId=fc521511e4267, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, objectTitle=ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床, objectType=article, longId=182745, objectId=f0a2182e457c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0a2182e457c, replyNumber=0, likeNumber=56, createdTime=2019-11-11, rootId=0, userName=ms5236388012055669, userId=474c10379153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0a2182e457c, moduleTitle=ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0a2182e457c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

拮抗剂

2020-05-29

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Nat Med：CXCR4拮抗剂+PD-1抑制剂+化疗三联疗法治疗胰腺癌获突破

2020-05-29

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Eur Heart J-Card Img：主动脉瓣钙化与维生素K拮抗剂治疗的关联

2020-05-08

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Brit J Cancer：质子泵抑制剂和组胺-2受体拮抗剂与胃癌风险

2020-05-07

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Brit J Heamatol：静脉血栓栓塞门诊患者维生素K拮抗剂治疗期间大出血的预测

2020-05-04

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

3期临床研究证实，促性腺激素释放激素（GnRH）受体拮抗剂Relugolix 显着减轻子宫内膜异位症女性的疼痛

2020-04-27

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Hypertension：IL-1受体拮抗剂可增加肥胖个体Ang（1-7)水平并降低血压

2020-04-14

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Ann Neurol：近期缺血性脑卒中的房颤患者直接口服抗凝剂与维生素K拮抗剂比较

2020-04-08

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

IL-5拮抗剂Nucala治疗慢性鼻-鼻窦炎的临床试验：取得阳性结果

2020-04-06

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌

2020-04-03

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Minerva Medica: ACEI与钙拮抗剂复方降压更优！意大利学者质疑欧洲指南：ARB和钙拮抗剂无证据

2020-03-01

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Clin Gastroenterology H：肿瘤坏死因子拮抗剂治疗难治性溃疡性直肠炎的疗效

2020-02-25

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

强生的雄激素受体拮抗剂Erleada，获得欧洲药品管理局批准治疗去势敏感型前列腺癌

2020-02-04

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Blood：MYC驱动的淋巴瘤进展需MYC拮抗剂MNT抑制MYC诱导的细胞凋亡

2020-02-03

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

FDA授予β3-肾上腺素能受体拮抗剂APD418用于代偿性心力衰竭治疗的快速通道指定

2020-01-19

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

BMJ：质子泵抑制剂和组胺受体拮抗剂对胃肠道出血的预防效果

2020-01-09

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Oncogene：拮抗剂贝沙罗汀靶向TR4核受体能够增加前列腺癌对多烯紫杉醇的敏感性

2019-12-06

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Myovant口服促性腺激素释放激素拮抗剂relugolix的前列腺癌III期试验成功

2019-11-24

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

阿斯利康的P2Y12受体拮抗剂Brilinta单一疗法可降低急性冠状动脉综合症患者的出血风险

2019-11-21

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

Science：谷氨酰胺拮抗剂——“代谢检查点”广谱抗癌药曙光初现

2019-11-14

ms5236388012055669 (审核中...)

前往app查看评论内容

#拮抗剂#

ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床

2019-11-11

科室
- - 订阅+
  - 更多科室
工具
服务